GPC3-targeted CAR macrophage
/ United Immunity
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
Myeloid-selective P-LNP enables in vivo engineering of GPC3-targeted CAR macrophages, resulting in robust tumor control and antitumor macrophage reprogramming
(SITC 2026)
- No abstract available
Preclinical • Oncology • GPC3
1 to 1
Of
1
Go to page
1